Cost-Effectiveness Analysis of Nirsevimab and Maternal Rsvpref Vaccine Strategies for Prevention of Respiratory Syncytial Virus Disease Among Infants in Canada: A Simulation Study

• 2023

  Log in to bookmark this resource.

  Log in
• Affan Shoukat; Elaheh Abdollahi; Alison Galvani; Scott Halperin; Joanne Langley; Seyed Moghadas
PMID: 38026446DOI: https://doi.org/10.1016/j.lana.2023.100629

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This study in Canada assessed cost-effectiveness of nirsevimab and RSVpreF for preventing RSV in infants. Modeling different interventions showed immunizing the birth cohort with nirsevimab is cost-effective under $290 per dose. A combined strategy for pregnant women and high-risk infants was also effective. Results suggest nirsevimab and RSVpreF could be cost-effective for infant protection.

---

Tags

Focus Area: Infectious Disease

Audiences: Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Canada; Cost-Benefit Analysis; Immunization; Infant; Infant, Newborn; Pregnancy; Pregnant Women; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vaccination; Antibodies, Monoclonal, Humanized

Institutions: Yale University; York University; Dalhousie University

---

More like this

The 2021 Toolkit for Emergency Preparedness and Mitigation to Combat Surge of Pediatric COVID-19 Patients in India: The World Health Organization Collaborating Center for Emergency and Trauma in South East Asia Recommendations 2021 · Florida State University, University of Nevada, Las Vegas, Manipal Academy of Higher Education, State University of New York Downstate Health Sciences University RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing 2024 · AstraZeneca, State University of New York - Upstate Medical University, Seattle Children's Hospital, Northwestern University Highly Pathogenic Avian Influenza H5N1: History, Current Situation, and Outlook 2025 · Icahn School of Medicine at Mount Sinai, Medical University of Vienna, University of Saskatchewan, University of New York at Stony Brook

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---